Ticker

/PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and

BOULDER, Colo., Feb. 25, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 10:30 a.m.

Shares of Enliven Therapeutics, Inc. (NASDAQ: ELVN - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the five research firms that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average

Heron Therapeutics (NASDAQ: HRTX - Get Free Report) and Enliven Therapeutics (NASDAQ: ELVN - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations. Insider and Institutional Ownership 80.0% of Heron

Enliven Therapeutics' Chief Scientific Officer sold 20,000 indirect shares for a total of approximately $535,100 on Jan. 20, 2026, at a weighted average price of around $26.75 per share. The sale represented 2.61% of the executive's holdings, reducing his trust's position from 765,188 to 745,188 shares as reported in the SEC Form 4.